CareDx Inc [NASDAQ: CDNA] plunged by -$5.23 during the normal trading session on Thursday and reaching a high of $16.25 during the day while it closed the day at $10.77. The company report on March 1, 2023 that CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023.
This marks the eighth consecutive year that CareDx is supporting NKF’s Annual Kidney Patient Summit, which is held each year in March in recognition of National Kidney Month, a time when communities across the country raise awareness about kidney disease.
CareDx Inc stock has also loss -24.83% of its value over the past 7 days. However, CDNA stock has declined by -10.74% in the 3 months of the year. Over the past six months meanwhile, it has lost -44.85% and lost -5.65% year-on date.
The market cap for CDNA stock reached $571.19 million, with 53.49 million shares outstanding and 52.24 million shares in the current float. Compared to the average trading volume of 969.90K shares, CDNA reached a trading volume of 14104748 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about CareDx Inc [CDNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CDNA shares is $26.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CDNA stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for CareDx Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 25, 2022. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on July 20, 2021, representing the official price target for CareDx Inc stock. Previously, the target price had yet another raise to $95, while Goldman analysts kept a Buy rating on CDNA stock.
The Average True Range (ATR) for CareDx Inc is set at 1.52, with the Price to Sales ratio for CDNA stock in the period of the last 12 months amounting to 1.79. The Price to Book ratio for the last quarter was 1.32, with the Price to Cash per share for the same quarter was set at 5.49.
CDNA stock trade performance evaluation
CareDx Inc [CDNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.83. With this latest performance, CDNA shares dropped by -27.95% in over the last four-week period, additionally sinking by -44.85% over the last 6 months – not to mention a drop of -71.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CDNA stock in for the last two-week period is set at 33.75, with the RSI for the last a single of trading hit 29.01, and the three-weeks RSI is set at 37.35 for CareDx Inc [CDNA]. The present Moving Average for the last 50 days of trading for this stock 13.92, while it was recorded at 14.55 for the last single week of trading, and 18.28 for the last 200 days.
CareDx Inc [CDNA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and CareDx Inc [CDNA] shares currently have an operating margin of -9.93 and a Gross Margin at +66.60. CareDx Inc’s Net Margin is presently recorded at -10.34.
Return on Equity for this stock declined to -8.25, with Return on Assets sitting at -6.41.
CareDx Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.30 and a Current Ratio set at 5.50.
Earnings per share (EPS) analysis for CareDx Inc [CDNA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CDNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CareDx Inc go to 20.00%.
CareDx Inc [CDNA]: Insider Ownership positions
There are presently around $627 million, in the hands of institutional investors. The top three institutional holders of CDNA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 6,188,182, which is approximately 6.93% of the company’s market cap and around 2.30% of the total institutional ownership; STATE STREET CORP, holding 5,747,244 shares of the stock with an approximate value of $61.87 million in CDNA stocks shares; and VANGUARD GROUP INC, currently with $56.74 million in CDNA stock with ownership of nearly 4.045% of the company’s market capitalization.
97 institutional holders increased their position in CareDx Inc [NASDAQ:CDNA] by around 9,520,526 shares. Additionally, 88 investors decreased positions by around 7,923,745 shares, while 25 investors held positions by with 40,778,616 shares. The mentioned changes placed institutional holdings at 58,222,887 shares, according to the latest SEC report filing. CDNA stock had 26 new institutional investments in for a total of 953,155 shares, while 35 institutional investors sold positions of 3,950,592 shares during the same period.